SPT Labtech strengthens company’s connection with Japanese market

Creating a new footprint in a vibrant life science community with enthusiastic plans for growth

Cambridge, UK, 14 July 2020. SPT Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science applications, has today announced the opening of their Japan office; the company’s second site in the APAC region. This increased presence will be headed by Masahiro Matsushita as Director. The expansion follows long-standing partnerships with Japanese life science distributors.

The move was motivated, in part, by growing biotech and healthcare markets in Japan. The increasing importance of the Japanese life science market and investment in valued techniques such as NGS and cryo-EM, coupled with the desire to further improve the connection to its customers, are all key contributors to SPT Labtech’s enhanced presence in the region.

Through world-leading application knowledge and engineering capabilities, SPT Labtech has designed and built a portfolio of liquid handling and sample management solutions that help improve efficiency, increase agility, support miniaturisation and streamline life science research. The range includes solutions for use across drug discovery, structural biology, genomics, cryo-EM, sample management and biobanking.

David Newble, Managing Director of SPT Labtech, said,
"Our ambition is to strengthen the company’s partnerships within the Japanese market and the establishment of a team in Japan will enable SPT Labtech to meet the needs of this community more effectively. From our existing sector presence, there is already much interest for our products and through collaboration, deep application knowledge and world-leading engineering, we look forward to working with more life scientists to help accelerate and elevate their research."

Masahiro Matsushita, Director SPT Labtech Japan, commented,
"With a flourishing life sciences industry in Japan and increasing adoption of laboratory automation, this is an ideal time for SPT Labtech to fully embed themselves in the region. With the opening of the new office, we are looking ahead to a collaborative future that will benefit clients and the life sciences community in Japan."

To learn more about SPT Labtech’s automation solutions for the drug discovery market, both in Japan and around the world, visit www.sptlabtech.com

About SPT Labtech:
SPT Labtech’s unique portfolio of automated sample management, liquid handling and sample preparation solutions are designed for discovery. Through collaboration, deep application knowledge and leading engineering, we enable drug discovery scientists to accelerate research through improved workflow efficiency, minimised assay volumes and reduced costs. Our essential tools include unique low-volume liquid handling for genomics, compound screening and protein crystallography (mosquito® X1, mosquito® HTS, mosquito® crystal, mosquito® LCP, mosquito® HV, dragonfly® crystal and dragonfly® discovery, plus a full range of validated consumables such as tips and plates). The range of products also includes state-of-the-art solutions developed for flexible sample management workflows from ambient to -800C (comPOUND®, arktic®, lab2lab).

In January 2020, SPT Labtech changed its name from TTP Labtech as part of a contractual requirement of its divestment from TTP Group in 2018 and marking a new chapter for the life science tools provider.